State Street SPDR S&P Biotech ETF (NY:XBI)

153.13 -3.06 (-1.96%)

Delayed Quote Updated: 11:52 AM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

“Should’ve Been Me” Stock Market (And Sentiment Results) ↗

June 23, 2022

In this week’s AAII Sentiment Survey result, bullish percent ticked down to 18.2% this week from 19.4% last week.

Via Talk Markets

Option Bears Reloading as Bulls Feeling Spry ↗

June 22, 2022

As the bulls have their moment, the bears are adding bearish options positions and rolling up into the strength.

Via Talk Markets

Stock Drop On June 16, But A Rally May Be Coming After Options Expiration ↗

June 16, 2022

Another miserable day for stocks, with the S&P 500 dropping 3.25%

Via Talk Markets

Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases? ↗

June 13, 2022

Crispr and Vertex tested their gene-edited drug in two blood diseases.

Via Investor's Business Daily

“Chip Shot” Stock Market (And Sentiment Results) ↗

June 02, 2022

Chips are the key to the economy/inflation moving forward. They are also the key to one of our major new positions in an auto-supplier

Via Talk Markets

The “Shake It Off” Stock Market (And Sentiment Results) ↗

April 07, 2022

We may be close to a short term peak in yields – bottom in bonds

Via Talk Markets

3 Biotech Stocks to Buy Before They Boom ↗

June 01, 2022

It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.

Via InvestorPlace

Again, Buy ‘Em ↗

May 31, 2022

Today we discuss again why it’s time to start adding back risk. We cover the major breadth thrusts that fired, some great monthly charts, and more.

Via Talk Markets

As COVID Subsidies, Here are 8 Infectious Diseases That Could Emerge As Potent Threats ↗

May 30, 2022

The COVID-19 pandemic that emerged in early 2020 doesn't seem to have run its course. Daily average cases, though have declined notably, stood at 110,084 in the U.S. as of Thursday, according to data...

Via Benzinga

PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst ↗

May 25, 2022

Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than...

Via Benzinga

This Biotech Looks Good With Increased M&A activity ↗

May 20, 2022

Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for...

Via Talk Markets

The “Mystery Liquidator Revealed” Stock Market (And Sentiment Results) ↗

May 19, 2022

In this week’s AAII Sentiment Survey result, Bullish Percent ticked up a hair to 26% this week from 24.3% last week. Bearish Percent rose to 50.4% from 49%.

Via Talk Markets

Large Cap Biopharmaceuticals: Provide Growth, Value And Yield ↗

May 16, 2022

Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing.

Via Talk Markets

When Will The Stock Market Stop Falling? ↗

May 12, 2022

Stocks have fallen dramatically just this past week, is a bottom near?

Via Talk Markets

Stocks Tank On May 11 With No Bottom In Sight ↗

May 11, 2022

Despite the sharp decline, the VIX finished down on the day at 32.5. It tells us there was “real” selling in the market today.

Via Talk Markets

7 Biotech Stocks With Key Catalysts for May ↗

May 11, 2022

The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns.

Via InvestorPlace

Should Biotech Be On The Critical List? ↗

May 11, 2022

The risk-off market has played havoc with the biotechs where the fundamentals have not changed as much as the valuation.

Via Talk Markets

“Threading The Needle” Stock Market (And Sentiment Results) ↗

May 05, 2022

Two weeks ago AAII sentiment survey dropped to a 30 year low at 15.8% bullish. Last week it ticked up modestly to 16.4%.

Via Talk Markets

7 Monster Stock Market Predictions For The Week Of April 25 ↗

April 23, 2022

The week ending April 22 was brutal. The S&P 500 fell by nearly 2.75%, but things were much worse than that. Powell unleashed hell when he noted that a 50 bps rate hike was on the table for the FOMC...

Via Talk Markets

The “magic Chart” Stock Market (And Sentiment Results) ↗

April 21, 2022

We have now come to a point Where the market has priced in more rate hikes than are likely to occur.

Via Talk Markets

4 Undervalued Biotech Stocks to Add to Your Buy List ↗

April 20, 2022

These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.

Via InvestorPlace

Healthcare Stocks Lead the Way Up as the Market Fades ↗

April 11, 2022

With inflation and energy costs soaring, the Fed ever threatening with higher rates and headlines from the war in Ukraine investors are seeking more defensive positions.

Via Talk Markets

Recession Fears are Creating a Golden Opportunity for Biotech Stocks ↗

April 08, 2022

Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now.

Via InvestorPlace

Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks ↗

April 08, 2022

Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies.

Via InvestorPlace

Sunshine Biopharma Stock Triples on Positive mRNA Cancer Treatment Results ↗

April 05, 2022

SBFM stock tripled to $6.53 on Tuesday after revealing that two of its newly designed mRNA molecules are effective in destroying cancer cells.

Via InvestorPlace

Good Entry Point for Biotech Stocks ↗

April 04, 2022

Life science and biotech stocks had a good week with the most well-known ETFs up 3-4% for the week and off recent bottoms.

Via Talk Markets

CNBC's Final Call: Newmont, Biotech ETF And This Energy Stock ↗

April 04, 2022

On CNBC's "The Final Call," Carter Worth recommended Newmont Corporation (NYSE: NEM). The stock has jumped almost 36% year to date.

Via Benzinga

Acadia: Helping With Alzheimers And Parkinsons ↗

April 03, 2022

Things always change fast in biotech, but until recently things have been moving consistently to the downside. It’s been a while, but we believe this is finally over. And we believe Acadia...

Via Talk Markets

Biotech Funds and ETFs Continue to Lag ↗

March 28, 2022

It’s no secret that market sectors driving inflation are leading the market. With the US economy still strong and the War in Ukraine limiting supply of nat gas and raw materials, producer costs are...

Via Talk Markets

How do Biotechnology Funds and ETFs Perform Over Five Years? ↗

March 21, 2022

Biotech investing can be difficult for short-term traders but can offer good returns over five years if balanced with other healthcare positions like the XLV.

Via Talk Markets

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.